Therapeutic Nuclear Drug Market Report 2024

This Therapeutic Nuclear Drug market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.69 billion in 2023 to $1.94 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The historical growth can be attributed to several factors, including increased regulatory approvals, greater use of patient-specific information, advancements in dosimetry techniques, rising awareness of nuclear medicines, and higher investments in research and development activities.

The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.36 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The anticipated growth during the forecast period can be attributed to several factors, including a shift towards personalized medicine, increased demand for improvements in healthcare infrastructure, a growing geriatric population, a rise in diagnostic imaging procedures, and the increasing focus on personalized care delivery. Key trends expected during this period include the development of nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, progress in radiopharmaceutical manufacturing and the development of alpha-emitting radiopharmaceuticals, and the integration of machine learning and artificial intelligence.

The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.

Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE’s AI solution, Pionus, into DeepC’s deepcOS platform, which enhances the interpretation of PET/CT scans.

In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix’s therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals.

North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.

The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.

The therapeutic nuclear drugs market research report is one of a series of new reports that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.